커넥티드 약물전달 기기 시장 보고서(2026년)
Connected Drug Delivery Devices Global Market Report 2026
상품코드 : 1951648
리서치사 : The Business Research Company
발행일 : On Demand Report
페이지 정보 : 영문 250 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,490 ₩ 6,822,000
PDF & Excel (Single User License) help
PDF & Excel 보고서를 1명만 이용할 수 있는 라이선스입니다. 문서의 일부나 표는 Copy & Paste 가능합니다만 챕터 전체는 불가합니다. 문서의 일부나 표는 Copy & Paste 가능합니다만 챕터 전체는 불가합니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF·Excel 이용 범위와 동일합니다.
US $ 6,490 ₩ 9,861,000
PDF & Excel (Site License) help
PDF & Excel 보고서를 동일 기업의 동일 사업장 내의 모든 분이 이용할 수 있는 라이선스입니다. 문서의 일부나 표는 Copy & Paste 가능합니다만 챕터 전체는 불가합니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF·Excel 이용 범위와 동일합니다.
US $ 8,490 ₩ 12,900,000
PDF & Excel (Enterprise License) help
PDF & Excel 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 문서의 일부나 표는 Copy & Paste 가능합니다만 챕터 전체는 불가합니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF·Excel 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

접속형 약물전달 기기 시장 규모는 최근 급격하게 확대하고 있습니다. 2025년 92억 7,000만 달러에서 2026년에는 114억 8,000만 달러로, CAGR 23.8%로 성장할 것으로 예상됩니다. 지난 수년간의 성장 요인으로는 만성질환 관리 기기의 보급 확대, 당뇨병 및 호흡기질환 유병률 증가, 스마트 주사기 및 흡입기 기술 발전, 의료 분야의 디지털화 추진, 복약 순응도에 대한 인식 증가 등을 꼽을 수 있습니다.

커넥티드 약물전달 기기 시장 규모는 향후 몇 년간 급격한 성장이 전망됩니다. 2030년에는 270억 2,000만 달러에 달하고, CAGR은 23.9%를 기록할 전망입니다. 예측 기간의 성장 요인으로는 원격 환자 모니터링 수요 증가, 커넥티드 의료 생태계 확대, AI 기반 예측 분석의 통합, 웨어러블 약물전달 기기의 성장, 디지털 헬스 도입을 지원하는 정부 정책 등을 꼽을 수 있습니다. 예측 기간의 주요 트렌드에는 개인화된 복약 순응도 모니터링, 원격 환자 모니터링 솔루션, 전자건강기록(EHR)과의 통합, 데이터 기반 투약량 최적화, 실시간 경고 및 알림 등이 포함될 것으로 보입니다.

원격 환자 모니터링의 중요성이 높아짐에 따라 향후 몇 년 동안 커넥티드 약물전달 기기 시장의 성장을 견인할 것으로 예상됩니다. 원격 환자 모니터링은 기술을 활용해 환자의 건강 상태와 의료 데이터를 원격으로 추적하는 의료 제공 방식입니다. 커넥티드 약물전달 기기는 약물 사용과 복약 순응도를 정밀하게 모니터링하고, 적시에 개입을 촉진하며, 개별화된 치료 관리를 제공함으로써 원격 환자 모니터링을 지원합니다. 예를 들어, 2024년 5월 캐나다에 기반을 둔 학술지 'Journal of Medical Internet Research'에 따르면 미국 성인의 38.78%가 지난 1년 동안 원격의료 서비스를 이용했다고 합니다. 따라서 원격 환자 모니터링의 중요성이 높아지면서 커넥티드 약물전달 기기 시장의 성장을 견인하고 있습니다.

커넥티드 약물전달 기기 시장의 주요 기업들은 치료 편의성 향상, 모니터링 정확도 강화, 자동화 치료 시스템과의 원활한 연결을 실현하는 첨단, 장수명, 통합성이 높은 디지털 헬스 솔루션 도입에 주력하고 있습니다. 예를 들어, 2025년 11월, 미국 의료 기업 덱콤(Dexcom)은 성인 당뇨병 환자를 위한 신제품 'G7 15 Day' 지속형 혈당 측정기를 2025년 12월 1일부터 미국에서 출시할 예정이라고 발표했습니다. FDA 승인을 받은 이 장치는 최대 15.5일간 사용이 가능하며, 정확도가 향상된 MARD(평균 상대오차) 8%를 실현하여 시장에서 가장 긴 착용 기간을 자랑하는 CGM이 될 수 있습니다. 출시 초기에는 의료기기 판매업체를 통해 구입할 수 있으며, 메디케어 사용자도 보험 적용을 받을 수 있습니다. 업데이트된 센서는 iLet 바이오닉 췌장, 옴니포드5, 그리고 가까운 탠덤 인슐린 펌프와도 연동이 가능하며, 덱콤의 새로운 시스템인 '스마트 베이스알'을 통한 인슐린 최적화도 지원합니다. G7 15 Day는 센서 교체 빈도 감소, 방수 설계, 스마트워치 연결 기능, 간소화된 기록 기능을 통해 편의성을 높이고 장기적인 혈당 관리를 개선할 수 있도록 설계되었습니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 공급망 분석

제4장 세계 시장 동향과 전략

제5장 최종 이용 산업 시장 분석

제6장 시장 : 금리, 인플레이션, 지정학, 무역 전쟁과 관세의 영향, 관세 전쟁과 무역 보호주의가 공급망에 미치는 영향, 코로나가 시장에 미치는 영향을 포함한 거시경제 시나리오

제7장 세계의 전략 분석 프레임워크, 현재 시장 규모, 시장 비교 및 성장률 분석

제8장 시장에서 세계의 총 잠재 시장 규모(TAM)

제9장 시장 세분화

제10장 지역별, 국가별 분석

제11장 아시아태평양 시장

제12장 중국 시장

제13장 인도 시장

제14장 일본 시장

제15장 호주 시장

제16장 인도네시아 시장

제17장 한국 시장

제18장 대만 시장

제19장 동남아시아 시장

제20장 서유럽 시장

제21장 영국 시장

제22장 독일 시장

제23장 프랑스 시장

제24장 이탈리아 시장

제25장 스페인 시장

제26장 동유럽 시장

제27장 러시아 시장

제28장 북미 시장

제29장 미국 시장

제30장 캐나다 시장

제31장 남미 시장

제32장 브라질 시장

제33장 중동 시장

제34장 아프리카 시장

제35장 시장 규제 상황과 투자 환경

제36장 경쟁 구도와 기업 개요

제37장 기타 주요 기업과 혁신적 기업

제38장 세계의 시장 경쟁 벤치마킹과 대시보드

제39장 주요 인수합병

제40장 시장 잠재력이 높은 국가, 부문, 전략

제41장 부록

KSM
영문 목차

영문목차

Connected drug delivery devices are smart pharmaceutical tools that use digital technology to monitor, manage, and control the administration of medications, improving adherence and patient outcomes. These devices can connect to the internet, enabling data sharing between patients and healthcare providers to track medication use, adjust dosages, and optimize treatment strategies.

The main types of connected drug delivery devices include standalone components, software, and integrated devices. Standalone components and software refer to hardware or software that can function independently or separately from the medical device with which it is used. These devices employ technologies such as Bluetooth, near-field communication (NFC), and others. The main routes of administration include parenteral and inhalational. They are applied in various areas, including asthma, chronic obstructive pulmonary disease, diabetes management, and others.

Tariffs have influenced the connected drug delivery devices market by increasing costs of components such as sensors, connectivity modules, and data analytics software, creating supply chain disruptions. The impact is most pronounced in segments like smart inhalers, smart auto-injectors, and connected syringes, particularly in Asia-Pacific manufacturing hubs such as China and India. While tariffs have raised production costs, they have also encouraged manufacturers to localize production, diversify sourcing, and accelerate innovation, potentially improving cost efficiency and product reliability in the long term.

The connected drug delivery devices market research report is one of a series of new reports from The Business Research Company that provides connected drug delivery devices market statistics, including connected drug delivery devices industry global market size, regional shares, competitors with a connected drug delivery devices market share, detailed connected drug delivery devices market segments, market trends and opportunities, and any further data you may need to thrive in the connected drug delivery devices industry. This connected drug delivery devices market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The connected drug delivery devices market size has grown exponentially in recent years. It will grow from $9.27 billion in 2025 to $11.48 billion in 2026 at a compound annual growth rate (CAGR) of 23.8%. The growth in the historic period can be attributed to growing adoption of chronic disease management devices, increasing prevalence of diabetes and respiratory disorders, technological advancements in smart syringes and inhalers, rising healthcare digitization initiatives, increasing awareness about medication adherence.

The connected drug delivery devices market size is expected to see exponential growth in the next few years. It will grow to $27.02 billion in 2030 at a compound annual growth rate (CAGR) of 23.9%. The growth in the forecast period can be attributed to rising demand for remote patient monitoring, expansion of connected healthcare ecosystems, integration of ai-based predictive analytics, growth of wearable drug delivery devices, supportive government initiatives for digital health adoption. Major trends in the forecast period include personalized medication adherence monitoring, remote patient monitoring solutions, integration with electronic health records (ehr), data-driven dose optimization, real-time alerts and notifications.

The growing significance of remote patient monitoring is expected to drive the expansion of the connected drug delivery device market in the coming years. Remote patient monitoring is a healthcare delivery approach that leverages technology to track patient health and medical data from a distance. Connected drug delivery devices support RPM by allowing precise monitoring of medication usage and adherence, enabling timely interventions, and providing personalized care management. For instance, in May 2024, the Journal of Medical Internet Research, a Canada-based peer-reviewed journal, reported that 38.78% of US adults had used telehealth services in the past year. Therefore, the increasing importance of remote patient monitoring is fueling growth in the connected drug delivery device market.

Major companies in the connected drug delivery device market are focusing on introducing advanced, longer-lasting, and more integrated digital health solutions that improve treatment convenience, enhance monitoring accuracy, and enable seamless connectivity with automated therapy systems. For instance, in November 2025, Dexcom, a US-based healthcare company, announced the launch of its new G7 15 Day continuous glucose monitor in the U.S. on December 1, 2025, for adults with diabetes. Recently cleared by the FDA, the device will become the longest-wearing CGM available, offering up to 15.5 days of use with an improved accuracy MARD of 8%. At launch, it will be accessible through DME providers and covered for Medicare users. The updated sensor integrates with the iLet Bionic Pancreas, Omnipod 5, and soon Tandem pumps, while also supporting Dexcom's new Smart Basal insulin optimization system. With fewer sensor replacements, a waterproof design, smartwatch connectivity, and simplified logging features, the G7 15 Day is designed to provide greater convenience and improved long-term glucose management.

In August 2023, Novo Nordisk A/S, a Denmark-based healthcare company, acquired BIOCORP Production SA for approximately €154 million (≈ $170 million). Through this acquisition, Novo Nordisk aimed to accelerate its digital drug-delivery strategy by incorporating Biocorp's Bluetooth-enabled smart sensor technology to enhance its connected pen injector offerings. BIOCORP, a France-based company, designs and manufactures innovative delivery systems, including the Mallya Bluetooth-enabled add-on cap for insulin pens, which enables automatic dose logging and connectivity.

Major companies operating in the connected drug delivery devices market are Pfizer Inc., Johnson & Johnson, Abbott Laboratories, Medtronic PLC, Eli Lilly and Company, Novo Nordisk A/S, Becton Dickinson and Company, Phillips-Medisize Corporation, AptarGroup Inc., Dexcom Inc., West Pharmaceutical Services Inc., Insulet Corporation, Tandem Diabetes Care Inc., Ypsomed AG, Meridian Medical Technologies LLC, Propeller Health, Findair Sp. z.o.o, Omron Healthcare Co. Ltd, Omnicell Inc., BD Medical

North America was the largest region in the connected drug delivery market in 2025. The regions covered in the connected drug delivery devices market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the connected drug delivery devices market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The connected drug delivery device market consists of revenues earned by entities by providing services such as medication reminders and alerts, dose tracking, data sharing, adjustable dosing, and integration with health records. The market value includes the value of related goods sold by the service provider or included within the service offering. The connected drug delivery device market also includes sales of smart inhalers, connected insulin pumps, smart pill dispensers, wearable drug delivery devices, and digital pills that are used in providing services. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Connected Drug Delivery Devices Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses connected drug delivery devices market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for connected drug delivery devices ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The connected drug delivery devices market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

Scope

Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.

Table of Contents

1. Executive Summary

2. Connected Drug Delivery Devices Market Characteristics

3. Connected Drug Delivery Devices Market Supply Chain Analysis

4. Global Connected Drug Delivery Devices Market Trends And Strategies

5. Connected Drug Delivery Devices Market Analysis Of End Use Industries

6. Connected Drug Delivery Devices Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, Supply Chain Impact from Tariff War & Trade Protectionism, And Covid And Recovery On The Market

7. Global Connected Drug Delivery Devices Strategic Analysis Framework, Current Market Size, Market Comparisons And Growth Rate Analysis

8. Global Connected Drug Delivery Devices Total Addressable Market (TAM) Analysis for the Market

9. Connected Drug Delivery Devices Market Segmentation

10. Connected Drug Delivery Devices Market Regional And Country Analysis

11. Asia-Pacific Connected Drug Delivery Devices Market

12. China Connected Drug Delivery Devices Market

13. India Connected Drug Delivery Devices Market

14. Japan Connected Drug Delivery Devices Market

15. Australia Connected Drug Delivery Devices Market

16. Indonesia Connected Drug Delivery Devices Market

17. South Korea Connected Drug Delivery Devices Market

18. Taiwan Connected Drug Delivery Devices Market

19. South East Asia Connected Drug Delivery Devices Market

20. Western Europe Connected Drug Delivery Devices Market

21. UK Connected Drug Delivery Devices Market

22. Germany Connected Drug Delivery Devices Market

23. France Connected Drug Delivery Devices Market

24. Italy Connected Drug Delivery Devices Market

25. Spain Connected Drug Delivery Devices Market

26. Eastern Europe Connected Drug Delivery Devices Market

27. Russia Connected Drug Delivery Devices Market

28. North America Connected Drug Delivery Devices Market

29. USA Connected Drug Delivery Devices Market

30. Canada Connected Drug Delivery Devices Market

31. South America Connected Drug Delivery Devices Market

32. Brazil Connected Drug Delivery Devices Market

33. Middle East Connected Drug Delivery Devices Market

34. Africa Connected Drug Delivery Devices Market

35. Connected Drug Delivery Devices Market Regulatory and Investment Landscape

36. Connected Drug Delivery Devices Market Competitive Landscape And Company Profiles

37. Connected Drug Delivery Devices Market Other Major And Innovative Companies

38. Global Connected Drug Delivery Devices Market Competitive Benchmarking And Dashboard

39. Key Mergers And Acquisitions In The Connected Drug Delivery Devices Market

40. Connected Drug Delivery Devices Market High Potential Countries, Segments and Strategies

41. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기